Industriebank Liof NV
Industriebank LIOF NV is a development and investment company based in Limburg, dedicated to enhancing the province's economic prosperity. It focuses on bolstering the local economy through its core activities, which include Acquisition, Participation, Development/Innovation, and the management of Business Parks. LIOF aims to attract and support the establishment of both domestic and foreign companies, provides venture capital to promising local businesses, and implements initiatives to enhance the competitiveness of Limburg's commercial landscape. Additionally, it coordinates the development of new business parks to create favorable conditions for growth. LIOF serves as a vital link between government entities and the business community, adopting a strategic approach that prioritizes long-term economic development. The organization is committed to understanding and addressing the needs of the business sector.
Top Stages
24 past transactions
SpecifAi Parking
Venture Round in 2024
SpecifAi Parking is a company that specializes in providing a parking intelligence platform, which centralizes and integrates parking data from multiple sources. Its system presents this information through user-friendly dashboards, allowing clients to easily access and interpret the data. By leveraging advanced analytics, SpecifAi Parking generates predictive insights that enable users to optimize their operations, enhance efficiency, and increase revenue. The platform is designed to support parking businesses in making informed decisions based on comprehensive data analysis.
Mosa Meat
Venture Round in 2024
Mosa Meat B.V. is a food technology company based in Maastricht, the Netherlands, founded in 2013. The company specializes in the mass production of cultured meat by employing tissue engineering techniques. It harvests adult stem cells from the muscle tissue of living cows without harming the animals, allowing for the production of real meat, including hamburgers, with significantly reduced environmental impact. By cultivating meat from cells rather than raising and slaughtering livestock, Mosa Meat aims to promote a more sustainable global food system, addressing issues related to emissions, land and water use, and animal welfare.
Ansana
Seed Round in 2023
Ansana specializes in developing innovative sterilization solutions for the pharmaceutical and healthcare sectors. Their technology significantly enhances patient safety by minimizing risks, reduces environmental impact, lowers operational costs, and improves process efficiency. The company's core offerings include sensors for critical process controls, enabling real-time data exchange and traceability, as well as robust, reusable sterilization containers designed for full traceability throughout the entire process flow. This allows healthcare providers and pharmaceutical companies to ensure instrument sterility in operating rooms while maintaining real-time parametric release and traceability.
Corporis Medical
Series B in 2023
Corporis Medical develops and commercializes diagnostic tools for minimally invasive surgery, focusing on laparoscopic and bowel procedures. Its devices help surgeons predict anastomosis quality during operations, reducing postoperative complications such as anastomotic leakages. By improving diagnostic accuracy and surgical outcomes, the company lowers healthcare costs and enhances access to effective surgical care.
MLA Diagnostics
Venture Round in 2023
MLA Diagnostics is focused on developing innovative diagnostic solutions, particularly the Ly75 indicator, which serves as a prognostic biomarker for early-stage melanoma. This in vitro diagnostic method effectively predicts patients' clinical outcomes, providing insight into a melanoma patient's metastatic risk. The Ly75 marker is designed to be inexpensive, robust, and efficient, allowing healthcare providers to make informed decisions about personalized treatment plans. By utilizing the results of the MLA Diagnostics biomarker test, patients and physicians can collaborate to select more effective treatment options, ultimately aiming to enhance patient well-being and outcomes.
Embrosa
Seed Round in 2023
Emborosa is a company that focuses on simplifying social media marketing for local entrepreneurs by providing a comprehensive platform tailored to their needs. It offers a range of marketing tools that include access to branded content, pre-prepared monthly Facebook planning, and personalized support. Additionally, Embrosa facilitates the scheduling of social media posts and provides educational courses for beginners, making social media marketing more accessible and manageable for users. The company aims to enhance the connection between brands and local retailers by streamlining the delivery of marketing content from headquarters to individual outlets around the world.
ToxGenSolutions
Grant in 2022
ToxGenSolutions is a biotechnology company that specializes in developing diagnostic tools for preclinical diagnostics, particularly targeting Alzheimer's Disease. The company employs (epi-)genetic approaches to address molecular initiation events and key adverse outcome pathways associated with various pathologies, including neurodegeneration, cancer, and immune dysfunction. By focusing on mechanism-based genetic signatures, ToxGenSolutions aims to identify and classify new leads and toxicants during the drug screening and development process. This innovative approach enables healthcare professionals to intervene early in the disease progression, ultimately enhancing safety assessments and improving therapeutic strategies in drug development.
Aerial Precision
Seed Round in 2022
Aerial Precision is a manufacturer of advanced 3D sensing systems specifically designed for commercial drones and mobile vehicles. The company focuses on light detection and ranging technology, utilizing sensors and artificial intelligence to deliver actionable insights from spatial data. Aerial Precision's systems enable the creation of real-time three-dimensional maps, facilitating informed decision-making processes for clients. By providing readily usable information, the company empowers users to access and comprehend drone data efficiently, regardless of location.
Neuroplast
Series B in 2021
Neuroplast is a biotechnology company developing a platform to enable autologous stem cell therapies and regenerative medicine. The platform focuses on isolating, manufacturing, and reinserting patients’ own cells to treat spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries, with the aim of delivering qualified autologous therapies to the global market and supporting physicians in improving patients’ quality of life.
Vertoro
Series A in 2021
Vertoro is a company that specializes in converting woody and agricultural residues into bio-based chemicals, materials, and fuels. It produces crude lignin oil and crude sugar oil from these residues, providing a sustainable alternative to fossil resources. The oils generated by Vertoro serve as liquid raw materials for the petrochemical industry and can effectively replace fossil crude oil in the production of various materials, chemicals, and fuels. By focusing on transforming waste into valuable resources, Vertoro aims to contribute to a more sustainable and circular economy.
Neuroplast
Funding Round in 2020
Neuroplast is a biotechnology company developing a platform to enable autologous stem cell therapies and regenerative medicine. The platform focuses on isolating, manufacturing, and reinserting patients’ own cells to treat spinal cord injuries, amyotrophic lateral sclerosis, and traumatic brain injuries, with the aim of delivering qualified autologous therapies to the global market and supporting physicians in improving patients’ quality of life.
Vacis
Venture Round in 2019
Vacis specializes in tissue engineering technology for creating body-own blood vessels. Its platform induces the body to form functional blood vessels, offering novel therapeutic options and reducing complications associated with prosthetic vascular grafts.
Paztir
Series A in 2019
Paztir offers an innovative solution for automating vehicle and box locks, enabling efficient access management and tracking for light electric vehicles. The company's system enhances traditional vehicles by integrating technology that provides lock automation, access control, and real-time vehicle tracking. This is particularly beneficial for delivery companies, electric cargo bike manufacturers, and bike leasing firms, as it allows them to optimize vehicle efficiency and enhance asset security. By implementing Paztir's technology, users can save significant time daily while gaining valuable insights into vehicle performance, thereby securing a competitive advantage in their respective markets.
Grassa
Series A in 2019
Grassa BV specializes in the valorization of plant-based streams through bioraffinage. Based in the Netherlands, Grassa converts grass and vegetable waste into high-quality, protein-rich animal feed and other valuable products using its mobile bio-refinery technology. This process generates four main outputs: fibers, protein, phosphate, and 'wei' (sap). By transforming locally available green residual flows such as grass from meadows, agricultural waste, water plants, or nature grass, Grassa supports sustainable agriculture and helps farmers enhance their income while addressing food scarcity.
Phenospex
Series A in 2018
Phenospex BV is a Netherlands-based company that specializes in developing a sensor platform and management system for automated assessment of plant growth dynamics. By integrating the analysis of plant parameters with environmental and climate factors, the company supports crop management and enhances decision-making in agriculture. Phenospex offers advanced digital phenotyping solutions that encompass sensors, software, and process automation, aiming to capture crop data and transform it into actionable insights. This technology is designed to accelerate the transition to sustainable agriculture by providing seed companies, crop protection firms, and indoor farms with real-time analysis capabilities. Their comprehensive approach allows clients to streamline their phenotyping processes, fostering innovation in agrochemical and crop development.
Cristal Therapeutics
Venture Round in 2017
Cristal Therapeutics BV, established in 2011 and headquartered in Maastricht, the Netherlands, operates as a clinical-stage pharmaceutical company specializing in nanomedicine development. The company's core business revolves around its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted delivery. Cristal Therapeutics focuses on treating diseases such as cancer by improving drug efficacy and safety profiles through this innovative technology.
Innosolids
Venture Round in 2015
Innosolids BV is a dynamic company based in Maastricht, the Netherlands, specializing in the production and supply of color solutions for the plastics industry. The company offers a diverse range of products including pigments, masterbatch, liquid colors, compounds, and micro beads, designed for various applications in sectors such as automotive, construction, and consumer goods. Innosolids also provides specialized additives like UV absorbers, heat stabilizers, and flame retardants, enhancing the performance and sustainability of plastic products. With a strong focus on research and development, supported by its proximity to the Brightland Campus in Geleen, Innosolids leverages innovative technology to improve the quality of plastic coloring while reducing costs and environmental impact. The company’s expertise in color development positions it as a key player in the European plastics market.
Quality Circular Polymers
Funding Round in 2014
Quality Circular Polymers specializes in the development of high-quality circular polymer compounds derived from recycled plastics. The company focuses on providing brand owners and plastic converters with sustainable solutions by transforming industrial waste into valuable materials. Through its innovative compounding technology, Quality Circular Polymers operates integrated recycling plants that facilitate the efficient reuse of plastics, offering an environmentally friendly alternative to traditional fossil-based feedstocks. This approach not only helps clients minimize waste but also supports broader sustainability goals within the industry.
Ekompany
Venture Round in 2013
Ekompany is a Dutch manufacturer specializing in coated mineral fertilizers, particularly controlled release fertilizers (CRF), which are designed to support agricultural and horticultural production. Established in 2010, the company operates from a state-of-the-art production facility in Born, which began operations in 2013. Ekompany has developed a patented coating process that is clean, safe, continuous, and energy-efficient, enabling the production of technologically advanced fertilizers. Their products, marketed under the Ekote portfolio, have demonstrated significant benefits through over 200 international field trials. With a team of experts in chemical, agricultural, and horticultural disciplines, Ekompany focuses on providing innovative solutions and sound advice to agricultural producers in Western Europe and the Far East.
Phenospex
Seed Round in 2011
Phenospex BV is a Netherlands-based company that specializes in developing a sensor platform and management system for automated assessment of plant growth dynamics. By integrating the analysis of plant parameters with environmental and climate factors, the company supports crop management and enhances decision-making in agriculture. Phenospex offers advanced digital phenotyping solutions that encompass sensors, software, and process automation, aiming to capture crop data and transform it into actionable insights. This technology is designed to accelerate the transition to sustainable agriculture by providing seed companies, crop protection firms, and indoor farms with real-time analysis capabilities. Their comprehensive approach allows clients to streamline their phenotyping processes, fostering innovation in agrochemical and crop development.
MagnaMedics
Series B in 2011
MagnaMedics specializes in the engineering and production of magnetic nano- and microparticles utilized in various medical applications, including medical devices, drug delivery tools, and diagnostic kits. The company's products facilitate the determination of biomarkers in body fluids, with a particular emphasis on proteomics. MagnaMedics is dedicated to high-quantity isolation of proteins, which supports research customers who are engaged in high-throughput screening of biomarkers. By providing innovative solutions, MagnaMedics enables manufacturers to conduct in-vitro diagnostics efficiently and effectively.
FABPulous
Series A in 2010
FABPulous is a healthcare company based in the Netherlands, established in 2008 as a spin-off from Maastricht University. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created an innovative handheld disposable plasma separation device that enables the rapid preparation of plasma from a single drop of blood. This technology presents significant advantages for point-of-care and home testing compared to existing methods. The company's initial product focuses on a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which assists healthcare providers in the first-line diagnosis of acute myocardial infarction. By integrating their plasma preparation device with various in vitro diagnostic platforms, FABPulous aims to enhance the speed and accuracy of diagnostic testing.
TiGenix
Private Equity Round in 2009
TiGenix NV is a Belgium-based biomedical company specializing in innovative treatments for damaged and osteoarthritic joints. Founded as a spin-off from the Catholic University of Leuven and the University of Ghent, TiGenix leverages regenerative medicine to create durable therapies validated through controlled clinical studies. The company focuses on developing a portfolio of products aimed at addressing specific musculoskeletal issues, with a primary emphasis on cartilage damage, which significantly impairs patient mobility and function. TiGenix also explores the anti-inflammatory properties of stem cells to create novel therapies for serious medical conditions, particularly in areas where there is a high unmet medical need.
Fortimedix
Venture Round in 2004
Fortimedix B.V., founded in 1999 and based in Nuth, the Netherlands, specializes in the development and manufacturing of endovascular, coronary, and peripheral stents. As a global leader in stent technology, the company has established a strong presence in the medical device industry, focusing on innovation and continuous improvement. With full in-house capabilities for stent development and production, Fortimedix is dedicated to operational excellence. The company prioritizes research and development to advance its technology and meet the evolving needs of its customers and stakeholders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.